The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Meiji Seika Pharma Partners with MPM BioImpact to Invest in New Technologies and Virology Strategy
Jan 10, 2025•over 1 year ago
Contract Type
partnership
TokyoBiotechnologyHealth CarePharmaceutical
Description
Meiji Seika Pharma Co., Ltd. has concluded a partnership with MPM BioImpact LLC, aiming to invest USD 20 million in new technologies and virology strategy. This strategic partnership will broaden Meiji’s perspective on early-stage opportunities and enhance its global network.
Company Information
Company
Meiji Seika Pharma Ltd
Location
Tokyo, Japan
About
Meiji Seika Pharma has been providing high-quality pharmaceutical products, including therapeutics and vaccines for infectious diseases, since it launched penicillin in 1946. The company also offers treatments for central nervous system diseases and generic drugs to meet various medical needs. With a commitment to safety management and stable product supply, Meiji Seika Pharma continues to adapt to public health challenges. Their investment in innovative vaccine technologies highlights their role in addressing future infectious disease threats.
Predictive Intelligence
Strategic
ML-powered predictions for Meiji Seika Pharma Ltd's next move
TokyoBiotechnologyHealth CarePharmaceutical